Harvard Bioscience (NASDAQ:HBIO) Share Price Crosses Below 200-Day Moving Average – What’s Next?

Harvard Bioscience, Inc. (NASDAQ:HBIO)’s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.56 and traded as low as $0.5409. Harvard Bioscience shares last traded at $0.5438, with a volume of 461,514 shares.

Analysts Set New Price Targets

A number of research analysts recently issued reports on HBIO shares. Wall Street Zen upgraded Harvard Bioscience from a “hold” rating to a “buy” rating in a report on Monday, November 17th. Zacks Research raised Harvard Bioscience to a “hold” rating in a research note on Thursday, December 11th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $2.00.

Harvard Bioscience Stock Performance

The stock has a market cap of $24.32 million, a P/E ratio of -0.45 and a beta of 1.55. The firm has a 50-day moving average price of $0.64 and a 200-day moving average price of $0.56.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Bank of America Corp DE grew its holdings in Harvard Bioscience by 44.4% in the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after purchasing an additional 11,948 shares during the period. Acadian Asset Management LLC boosted its position in shares of Harvard Bioscience by 7.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock worth $606,000 after purchasing an additional 78,276 shares in the last quarter. Strs Ohio purchased a new stake in shares of Harvard Bioscience in the 1st quarter worth approximately $117,000. Pasadena Private Wealth LLC increased its position in Harvard Bioscience by 23.2% during the 2nd quarter. Pasadena Private Wealth LLC now owns 243,911 shares of the medical instruments supplier’s stock valued at $108,000 after buying an additional 45,872 shares in the last quarter. Finally, AMH Equity Ltd raised its stake in Harvard Bioscience by 3.6% during the second quarter. AMH Equity Ltd now owns 3,508,703 shares of the medical instruments supplier’s stock valued at $1,557,000 after buying an additional 121,348 shares during the last quarter. 80.87% of the stock is owned by hedge funds and other institutional investors.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.